Regarding trials reporting results in 2008, I think Bromley hit on a few of the key ones, but I looked a bit through the phase 2 list to see what studies might wrap up thsi year. As mentioned, the PPMS phase 2/3 for rituxan should report this year, and if the results are good, that would be the biggest news in MS research since interferon was approved back in the early 1990s. Also mentioned by Bromley, the lamotrigine trial to stop progression could also be big news this year.
Other trials that might be reporting in 2008 are: ATL1102 (same target as Tysabri), daclizumab (reported decent interim results last year), pravastatin (should have wrapped up last year, but I can't find any info), LDN (study in California is done I think, we're just waiting for results), topamax with avonex, albuterol with copaxone, and last but not least and I can't believe I'm bringing this up and not somebody actually taking it, the tovaxin trial should end in September (or do I have my dates wrong?), so we could hear something before year-end.